KNB Kanabo Group Plc

TIDMKNB

RNS Number : 4722Z

Kanabo Group PLC

16 May 2023

16 May 2023

Kanabo Group Plc

("Kanabo" or the "Company")

Amendments to The GP Service Limited Acquisition Agreement

Further to the acquisition of The GP Service Limited (the "GP Service"), as announced on 21 February 2022, and p ursuant to a sale and purchase agreement (the "Agreement"), Kanabo was due to issue 12,574,931 Ordinary Shares to MEIF WM Debt LP ("MEIF") in satisfaction of the MEIF loan.

The Company negotiated with MEIF and agreed that in respect of the 12,574,931 Ordinary Shares due to be issued and sold by Kanabo to satisfy the MEIF loan, the definition of "Final Repayment Date" in the original MEIF loan agreement shall be extended to 31 December 2024 or such later date as determined by MEIF. It was also agreed that if the Company, at its discretion and at any time prior to the Final Repayment Date, finds buyers for the 12,574,931 Ordinary Shares it will do so to satisfy the loan repayment.

Defined terms in this announcement shall have the same meaning as set out in the Acquisition of The GP Service Limited announcement made on 21 February 2022, unless otherwise specified herein.

For further information, please contact:

 
 Kanabo Group Plc 
 Avihu Tamir, Chief Executive Officer                    via Vigo Consulting 
  Assaf Vardimon, Chief Financial Officer                 +44 (0)20 7390 
  Ian Mattioli, Non-Executive Chair of the                0230 
  Board 
 Peterhouse Capital Ltd (Financial Adviser 
  and Broker)                                            +44 (0)20 7469 
  Eran Zucker/ Lucy Williams / Charles Goodfellow         0930 
 Vigo Consulting (Financial Public Relations/Investor 
  Relations) 
  Jeremy Garcia / Fiona Hetherington / Verity 
  Snow                                                    +44 (0)20 7390 
  kanabo@vigoconsulting.com                                0230 
 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKPBPPBKDFPD

(END) Dow Jones Newswires

May 16, 2023 02:00 ET (06:00 GMT)

Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024